European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives

[1]  P. Valent,et al.  Diagnosis, progression patterns and prognostication in mastocytosis , 2012, Expert review of hematology.

[2]  M. Triggiani,et al.  Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal , 2011, International Archives of Allergy and Immunology.

[3]  P. Valent,et al.  Mast cell activation syndrome: Proposed diagnostic criteria. , 2010, The Journal of allergy and clinical immunology.

[4]  P. Valent,et al.  Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives , 2010, Expert review of hematology.

[5]  H. Sokol,et al.  Gastrointestinal involvement and manifestations in systemic mastocytosis , 2010, Inflammatory bowel diseases.

[6]  A. Tefferi,et al.  WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. , 2010, Blood.

[7]  P. Valent,et al.  Midostaurin (PKC412) inhibits immunoglobulin E‐dependent activation and mediator release in human blood basophils and mast cells , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[8]  A. Tefferi,et al.  Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. , 2009, Blood.

[9]  G. Passalacqua,et al.  Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. , 2009, The Journal of allergy and clinical immunology.

[10]  D. Metcalfe.  Mast cells and mastocytosis. , 2008, Blood.

[11]  J. Ring,et al.  Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients , 2008, Allergy.

[12]  F. Sim,et al.  Mastocytosis (Mast Cell Disease) , 2008 .

[13]  D. Fabbro,et al.  Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT , 2007, Haematologica.

[14]  M. Triggiani,et al.  Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria , 2007, European journal of clinical investigation.

[15]  K. Sotlar,et al.  Mastocytosis: State of the Art , 2007, Pathobiology.

[16]  P. Valent,et al.  Diagnostic and Subdiagnostic Accumulation of Mast Cells in the Bone Marrow of Patients with Anaphylaxis: Monoclonal Mast Cell Activation Syndrome , 2006, International Archives of Allergy and Immunology.

[17]  D. Fabbro,et al.  PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. , 2006, Blood.

[18]  C. Chen,et al.  Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. , 2005, Blood.

[19]  P. Valent,et al.  Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. , 2004, The Journal of allergy and clinical immunology.

[20]  K. Sotlar,et al.  Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge , 2004, Journal of Clinical Pathology.

[21]  K. Wolff,et al.  The European Competence Network on Mastocytosis (ECNM). , 2004, Wiener klinische Wochenschrift.

[22]  P. Valent,et al.  Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. , 2003, Hematology/oncology clinics of North America.

[23]  J. Bennett,et al.  Diagnosis and treatment of systemic mastocytosis: state of the art , 2003, British journal of haematology.

[24]  G. Mufti,et al.  Erythema following imatinib mesylate , 2003, British journal of haematology.

[25]  J. Bennett,et al.  Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. , 2003, Leukemia research.

[26]  A. Órfão,et al.  Mastocytosis: current concepts in diagnosis and treatment , 2002, Annals of Hematology.

[27]  D. Hossfeld.  E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .

[28]  K. Austen,et al.  Mastocytosis: Mediator-Related Signs and Symptoms , 2002, International Archives of Allergy and Immunology.

[29]  P. Valent,et al.  Spectrum of Associated Clonal Hematologic Non-Mast Cell Lineage Disorders Occurring in Patients with Systemic Mastocytosis , 2002, International Archives of Allergy and Immunology.

[30]  K. Hartmann,et al.  Cutaneous Mastocytosis – Clinical Heterogeneity , 2002, International Archives of Allergy and Immunology.

[31]  K. Lennert,et al.  Diagnostic criteria and classification of mastocytosis: a consensus proposal. , 2001, Leukemia research.

[32]  P. Valent,et al.  Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. , 2001, Leukemia research.

[33]  P. Valent,et al.  Mutation analysis of C‐KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis , 2001, British journal of haematology.

[34]  A. Rogers,et al.  Systemic Mastocytosis , 2000, Digestive Diseases.

[35]  R. Parwaresch,et al.  Recent Advances in Mastocytosis Research , 1999, International Archives of Allergy and Immunology.

[36]  R. Parwaresch,et al.  Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998. , 1999, International Archives of Allergy and Immunology.

[37]  K. Lennert,et al.  Diagnostic value of immunostaining for tryptase in patients with mastocytosis. , 1998, The American journal of surgical pathology.

[38]  A. Órfão,et al.  Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. , 1998, Blood.

[39]  Laura H. Tang,et al.  Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm , 1996, Nature Genetics.

[40]  R. O’Keefe,et al.  Mastocytosis presenting as a skeletal disorder. , 1996, The Iowa orthopaedic journal.

[41]  P. Valent,et al.  Biology, classification and treatment of human mastocytosis. , 1996, Wiener klinische Wochenschrift.

[42]  B. Zweiman,et al.  The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. , 1995, The Journal of clinical investigation.

[43]  Y. Suzuki,et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Metcalfe,et al.  Classification and diagnosis of mastocytosis: current status. , 1991, The Journal of investigative dermatology.

[45]  K. Lennert,et al.  Mast cells and mast cell neoplasia: a review * , 1979, Histopathology.

[46]  J. J. Will,et al.  Tissue mast cell leukemia. , 1958, Blood.

[47]  A. Klajman,et al.  Mast cell leukemia? Malignant mastocytosis with leukemia-like manifestations. , 1957, Blood.

[48]  Ellis Jm.  Urticaria pigmentosa; a report of a case with autopsy. , 1949 .

[49]  J. Ellis.  Urticaria pigmentosa; a report of a case with autopsy. , 1949, Archives of pathology.